Contrasting Mangoceuticals (NASDAQ:MGRX) and biote (NASDAQ:BTMD)

biote (NASDAQ:BTMD) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Earnings & Valuation

This table compares biote and Mangoceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22 million	0.30	$27.05 million	$0.11	14.36
Mangoceuticals	$460,000.00	18.18	-$20.64 million	($1.01)	-0.38

biote has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for biote and Mangoceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1	1	1	1	2.50
Mangoceuticals	1	0	0	0	1.00

biote presently has a consensus target price of $2.50, indicating a potential upside of 58.23%. Given biote’s stronger consensus rating and higher probable upside, equities research analysts clearly believe biote is more favorable than Mangoceuticals.

Profitability

This table compares biote and Mangoceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
biote	3.19%	-22.33%	12.10%
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

Risk and Volatility

biote has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.

Institutional and Insider Ownership

21.7% of biote shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

biote beats Mangoceuticals on 12 of the 15 factors compared between the two stocks.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

About Mangoceuticals

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.